We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Soy Isoflavone Supplementation on Endothelial Function

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01463436
First Posted: November 1, 2011
Last Update Posted: November 2, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Dr. dr. Pusparini SpPK, Trisakti University
  Purpose
A randomized double blind controlled trial was conducted to evaluate the effect of daily supplementation with soy isoflavone 100 mg/day for 12 months on 182 postmenopausal women aged 47 to 60 years at subdistrict South Jakarta Indonesia. The study hypothesis was supplementation soy isoflavone 100 mg/day for 6 and 12 months can increase endothelial function.

Condition Intervention Phase
Cardiovascular Disease Osteoporosis Dietary Supplement: soy isoflavone Dietary Supplement: control group Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Study of Soy Isoflavone 100 mg/Day in Postmenopausal Women to Elaborate the Effect of Soy Isoflavone in Endothelial Function and to Reduce Oxidative Stress

Resource links provided by NLM:


Further study details as provided by Dr. dr. Pusparini SpPK, Trisakti University:

Primary Outcome Measures:
  • the changes levels of endothelial function marker in blood after 13 months supplementation [ Time Frame: 13 months ]
    this study were measured the change levels of vascular cell adhesion molecule-1 (VCAM-1), nitric oxide (NO) as endothelial function parameter and malonyldialdehide as lipid peroxidation parameter from baseline to 6 months supplementation and from baseline to 13 months supplementation


Secondary Outcome Measures:
  • the changes levels of osteoporosis parameter after 6 months supplementation [ Time Frame: 6 months ]
    This study have another outcome such as rank ligand, C telopeptide and osteoprotegrin as marker of osteoporosis. We will be measured the changes levels of osteoporosis marker after 6 months supplementation


Enrollment: 200
Study Start Date: January 2010
Study Completion Date: February 2011
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: soy isoflavone 100 mg
the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg
Dietary Supplement: soy isoflavone
100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
Other Name: kacang kedelai, soya bean
Placebo Comparator: calcium carbonate 500 mg
The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months
Dietary Supplement: control group
the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
Other Name: plasebo

Detailed Description:

The subject were randomized to the intervention group receiving tablets consisting of 100 mg soy isoflavone and calcium carbonate 500 mg and the control group receiving 500 mg calcium carbonate for 1 year. This study was carried out 13 months(13 x 28 days).

There were three outcome measure from this study; vascular cell adhesion molecule-(VCAM-1), nitric oxide (NO) and malonyldialdehyde (MDA). The outcome measure will be assessed at three times; before soy isoflavone supplementation / the beginning of study,post supplementation 6 months and 12 months. The outcome will be measured change from baseline in the level of VCAM-1, NO and MDA.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   47 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy postmenopausal women
  • natural cessation 1-10 years
  • body mass index <=35 kg/m2
  • not receiving medication and supplement in the previous 6 months

Exclusion Criteria:

  • has chronic or terminal disease
  • severe psychosis
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01463436


Locations
Indonesia
Trisakti University
Jakarta, DKI Jakarta, Indonesia
Sponsors and Collaborators
Trisakti University
Investigators
Principal Investigator: Pusparini Sunarno, Doctor Trisakti University
  More Information

Additional Information:
Publications:
Hall WL, Rimbach G, Williams CM. isoflavones and endothelial function. Nutrion Research Review 18:123-131, 2005. Vincent A,Fitzpatrick LA. soy Isoflavone: are they useful in menopause? Mayo clinic Proceeding 75:1171-1184, 2000

Responsible Party: Dr. dr. Pusparini SpPK, Principal investigator, staff of Clinical Pathology Department, Trisakti University
ClinicalTrials.gov Identifier: NCT01463436     History of Changes
Other Study ID Numbers: Usakti
First Submitted: October 25, 2011
First Posted: November 1, 2011
Last Update Posted: November 2, 2011
Last Verified: November 2011

Keywords provided by Dr. dr. Pusparini SpPK, Trisakti University:
endothelial function
postmenopausal
soy isoflavone supplementation
osteoporosis

Additional relevant MeSH terms:
Cardiovascular Diseases
Osteoporosis
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Calcium, Dietary
Calcium Carbonate
Bone Density Conservation Agents
Physiological Effects of Drugs
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents